Systemic inflammation is closely associated with the development and progression of heart failure (HF). The study assessed the fibrin/albumin (FAR) ratio, a very important biomarker, as a prognostic indicator of HE. Study population is composed by patients who were addicted with heart failure diagnosed for the first time or already under treatment (NYHA class II-IV) and reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).
Prospective, observational, single-center study, which involves the enrollment of patients affected by heart failure of first diagnosis or already in therapy, who will be subjected to an analysis of the Albumin/fibrinogen ratio. Subjects will not be subjected to specific visits or services for the study: clinical and anamnestic data will be collected during routine visits.
Study Type
OBSERVATIONAL
Enrollment
114
Given the observational nature of the study, the intervention is a simple data collection
IRCCS Ospedale Galeazzi-Sant'Ambrogio
Milan, Italy, Italy
IRCCS Galeazzi-Sant'Ambrogio
Milan, Italy
Evaluation of FAR
Evaluate FAR (=Fibrin/Albumin) in heart failure HFrEF and HFpEF with or without atrial fibrillation.
Time frame: At Hospital admission
FAR (=Fibrinogen/Albumin) and functional ultrasound
Correlate FAR to functional ultrasound indices of atrium and ventricle and to the presence of atrial fibrillation.
Time frame: At Hospital admission and at hospital discharge (assessed up to 1 months)
Direzione Scientifica Direzione Scientifica
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.